about
Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 DiabetesThe Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes MellitusStudy to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without BendaviaPharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult SubjectsA Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DMA Study of SYNT001 in Healthy VolunteersA Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy ParticipantsA Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney FunctionEvaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy AdultsMAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DMPharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal FunctionPharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy VolunteersA Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal ImpairmentA Study to Evaluate the Effect of Renal Function on the Biological Activity of TelavancinCo-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy VolunteersAn Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired ParticipantsA Study of LY3314814 in Participants With Liver ImpairmentThe Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa AntagonistStudy to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionThe Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
P6153
Q61907402-12FB271B-299D-4314-979F-9CF5AA6F5AB8Q61936954-F6A5868E-FF67-41DA-BCDC-1E9CEEA02818Q61955704-947CA0A1-E21C-4B41-8F7A-09E70EAC97B9Q61970197-F290291C-B37B-487E-BF3F-08FE70F3A278Q62025724-331B3B7B-802C-46CE-9746-60C5535E7137Q62025973-BF7AD49D-3853-4CF2-AB4B-88819F9B173EQ62810430-A95CDE04-A752-4FBA-AF45-52A9D3DD1C7EQ62810946-D7F2CB9F-2A1C-402A-B01E-87BFEA6AE212Q63062710-BF67CA5F-3BD0-40E6-B752-3CD631DF5711Q63228948-3973F03C-9D06-4D51-B95E-8B2574936165Q63318483-6AFB049D-FB5E-40B8-B66D-62CCEF6617C3Q63333978-DFB3CB3A-488F-458A-ADC7-96E45E9A31C6Q63337030-00696BD2-DC40-4123-917E-AEE8B573A5C9Q63340448-D3F6CCAC-A7E8-43AE-8338-D4E97724A246Q63340756-974EF10F-2BCE-447E-A389-9D71C004F16FQ63394299-FFA9C14D-4253-4103-87C4-158032D59CA5Q63399711-63ABEF2D-4762-4C7B-9944-D003A2AC1F90Q63402952-8A143B37-A12D-42EE-A9B5-A7106BCF32DCQ63404353-CC6955C6-A23D-479D-AD9E-76325AE9CC36Q63578982-DDFD3A38-77F3-4C1F-BDCF-9F642323570D
P6153
description
griya sakit
@jv
healthcare organization in Hialeah, United States
@en
rumah sakik
@min
rumah sakit di Amerika Serikat
@id
rumoh sakét
@ace
مستشفى في هياليه، فلوريدا، الولايات المتحدة
@ar
name
Clinical Pharmacology of Miami
@en
type
label
Clinical Pharmacology of Miami
@en
altLabel
CPMI
@en
prefLabel
Clinical Pharmacology of Miami
@en
P131
P2427
grid.490032.c
P571
2006-01-01T00:00:00Z
P625
Point (-80.295072 25.899504)